Avid Bioservices Inc (CDMO)

[ststephensrevenge]

While the amount of time taken by the FDA to iron out an “agreeable” phase III protocol is ridiculously slow, I don’t believe it can be used as a gauge to determine what the outcome will be. The fact that the process is going on 5 months is lame even with the unique “control arm” issue. I’m somehow not surprised though.

The leaders of this company and board appear to be something closely resembling a group of human lampreys and the retail shareholders have served as the hosts. How they have retained control of the company this long with their attitude and track record towards shareholders is troubling….especially given their latest silence and lack of leadership.

The bar is set so low for the 2nd line lung cancer SOC. I still somehow remain optimistic for a successful outcome. Front line is still very much in play. I expect the MOS results to surpass SOC at the end of the trial. Declaring that trial a failure is way premature. The Bavi arm results were spot on with prior trials. I use the average of past historical chemo results as the ultimate measuring stick. Pancreatic and Liver initial results to be presented this year as well shouldn’t be discounted because of the beat to crap share price / market cap. I am still shaking my head as to why no progress has been made given the impressive breast cancer results from previous trials. Maybe I am missing something there.

In the event Cotara and the 2nd line news comes in favorable, the stock should find a valuation way north of where is stands today as it relates to both….ie zero. Up front $ and a respectable partner for Cotara buys the company the time for the rest of the cards to be played by year end. We are obviously running out of time though.

All IMHO.